IN THE CLAIMS

Claim 1 (original): A wound care device comprising an active pain killing agent, said device being capable of releasing a painkilling agent to a wound even when only low levels of exudates are present, that supplies pain relief locally to a wound and nearby surroundings and wherein at least 50% w/w of the pain-killing agent is released during the first 24 hours after application and wherein a majority of said pain killing agent is in direct contact with the wound.

Claim 2 (original): A wound care device according to claim 1 wherein the amount of pain killing agent in the device is below the lowest daily unit dose for systemic treatment.

Claim 3 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein the pain-killing agent is an anti-inflammatory pain-killing agent.

Claim 4 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein the device has a maximum absorption of 0,2 g/cm^2.

Claim 5 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein the device is substantially non-absorbent.

Claim 6 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein the release of the pain-killing agent is substantially independent of the amount of wound exudate.

Claim 7 (currently amended): A wound care device according to claim 1 ~~any of the preceding claims~~ wherein the pain killing agent is released to the wound in such a way that substantially no effective systemic plasma concentration of the pain killing agent can be found.

Claim 8 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein at least 50% w/w of the pain-killing agent is released during the first 12 hours after application.

Claim 9 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein at least 50% w/w of the pain-killing agent is released during the first 6 hours after application.

Claim 10 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein at least 75% w/w of the pain-killing agent is released during the first 24 hours after application.

Claim 11 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein at least 75% w/w of the pain-killing agent is released during the first 12 hours after application.

Claim 12 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein at least 75% w/w of the pain-killing agent is released during the first 6 hours after application.

Claim 13 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein at least 90% w/w of the pain-

killing agent is released during the first 24 hours after application.

Claim 14 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein at least 90% w/w of the pain-killing agent is released during the first 12 hours after application.

Claim 15 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein at least 90% w/w of the pain-killing agent is released during the first 6 hours after application.

Claim 16 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein the device comprises one or more components selected from the group of PVP, PVA, polylactic acids, polysaccharides such as carboxy methyl cellulose, hydroxymethyl cellulose, chitosan, alginate, or polyacrylic acids, methacrylates, silicones, styrene-isoprene-styrene mixtures, vaseline, glycols such as PEG or PEG/PPG mixtures or polyurethane.

Claim 17 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein the amount of pain killing agent is less than 75% of the daily unit dose for systemic treatment using the agent.

Claim 18 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein the amount of pain killing agent is less than 50% of the daily unit dose for systemic treatment using the agent.

Claim 19 (currently amended): A device according to claim 1 ~~any of the preceding claims~~, wherein the pain-killing agent is a NSAID.

Claim 20 (currently amended): A device according to claim 1 ~~any of the preceding claim~~s, wherein the pain-killing agent is ibuprofen.

Claim 21 (currently amended): A wound care device according to claim 1 ~~any of the preceding claims~~ wherein the pain killing agent is provided on the wound facing surface of the device.

Claim 22 (currently amended): A wound care device according to claim 1 ~~any of claims 1-20~~ wherein the pain killing agent is provided in a relatively thin wound-contacting layer.

Claim 23 (currently amended): A wound care device according to claim 1 ~~any of the preceding claims~~ wherein the device has a thickness of less than1,5 mm.

Claim 24 (currently amended): A wound care device according to claim 1 ~~any of the preceding claims~~ wherein the device exhibits non-stick properties with regards to the wound.

Claim 25 (currently amended): A wound care device according to claim 1 ~~any of the preceding claims~~ wherein the device is in the form of a sheet-like layer.

Claim 26 (original): A wound care device according to claim 25 wherein the layer is prepared from a web, a net, a knit, a woven or a non-woven fabric, a permeable or perforated film or a foam or a hydrogel.

Claim 27 (currently amended): A wound care device according to claim 1 ~~any of the preceding claims~~ wherein the device is in the form of an open fabric being coated or impregnated with a composition comprising the pain-killing agent.

Claim 28 (original): A wound care device according to claim 27 wherein the composition further comprises a non-stick agent.

Claim 29 (original): A method of treating pain at a wound site comprising applying to the wound a wound care device comprising an active pain relieving composition, said composition is an anti-inflammatory pain killing agent, wherein the amount of pain killing agent in the device is below the daily unit dose for systemic treatment and wherein a majority of the pain killing agent is brought into direct contact with the wound.